Condiciones de salud que forsitia puede ayudar a apoyar.
Forsythia suspensa and its active compounds, particularly forsythoside A and the lignans phillyrin and pinoresinol, have well-documented antioxidant properties across multiple in vitro assay systems. These include dose-dependent scavenging of DPPH free radicals and hydroxyl free radicals. Antioxidant activity is considered a primary pharmacological property underlying many of its other effects.
Pharmacological reviews identify 'alleviate asthma' as one of the documented activities of Forsythia suspensa compounds, particularly phillyrin, which is a PDE4 inhibitor. Phillyrin's cyclic AMP phosphodiesterase inhibitory activity is mechanistically relevant to bronchodilation and airway inflammation. Evidence is preclinical only.
Preclinical research has demonstrated that a water extract of Forsythia suspensa reduces bone loss in ovariectomized mice by inhibiting RANKL-induced osteoclast formation and resorption. It suppresses key osteoclast differentiation signaling pathways involving p38 and JNK. Evidence is currently limited to animal models; no human clinical trials on bone density exist.
Multiple preclinical studies have characterized the anti-inflammatory properties of Forsythia suspensa extracts and its active compounds, particularly forsythoside A and phillyrin. These act via inhibition of TLR4/NF-κB and related pathways. The evidence comes from in vitro and animal studies; no human clinical trials for general chronic inflammation have been conducted.
Neuroprotective and anti-aging properties of Forsythia suspensa have been documented in preclinical studies relevant to Alzheimer's disease, Parkinson's disease, and cognitive aging. Forsythia leaves and flowers show significant anti-aging properties in vitro. Forsythoside A modulates neurodegenerative signaling pathways. Evidence is from animal/in vitro studies; no human trials have been conducted.
A PLoS ONE animal study (2016) demonstrated that Forsythia suspensa extract suppressed house dust mite-induced atopic dermatitis in NC/Nga mice, reducing IgE, TNF-α, histamine, and inflammatory chemokines. The active constituents forsythiaside, phillyrin, pinoresinol, and phylligenin were identified as mediating chemokine suppression in human keratinocytes. Evidence is preclinical; no human RCTs have been conducted.
Forsythiaside A from Forsythia suspensa has been studied in a preclinical androgenic alopecia mouse model, showing significant protective effects on hair follicle density, thickness, and anagen/telogen ratio compared to both DHT-treated controls and finasteride. The compound inhibits DHT-induced apoptosis in human hair dermal papilla cells in vitro. No human clinical trials exist.
Forsythiasides—the phenylethanol glycosides of Forsythia suspensa—have been shown in preclinical studies to exert cardiovascular protective effects, with forsythoside A demonstrating antioxidant and cardioprotective properties in experimental models. Forsythia is also traditionally used as a cardiovascular tonic. No large human clinical trials for heart health specifically have been published.
Preclinical research has identified nephroprotective properties of Forsythia suspensa, particularly forsythoside A, in models of sepsis-related acute kidney injury and nephrotoxicity. Pharmacological review literature characterizes nephroprotective activity as one of its documented activities. No human clinical trials specifically assessing kidney health endpoints have been published.
Forsythia suspensa has documented hepatoprotective activity, with multiple preclinical studies identifying liver-protective compounds including new iridoid glycosides. Forsythoside A exerts hepatoprotective effects via antioxidant mechanisms including MDA clearance. Animal models show it can prevent fulminant hepatitis. Human clinical trials are lacking.
Forsythia acts on the lung meridian in TCM and has substantial preclinical evidence for protecting lung tissue from acute injury and viral infection. Forsythoside A protects mice from LPS-induced acute lung injury. Studies also show efficacy against RSV-induced pneumonia and influenza in animal models. Combination formulas containing Forsythia have documented clinical use for lung infections in China.
The same 2015 Phytotherapy Research study by Shin HS et al. specifically modeled androgenic (male pattern) alopecia using DHT induction. Forsythiaside A outperformed finasteride in protecting hair follicles from DHT-induced damage in vitro and in vivo. This is the same scientific evidence as for Hair Loss above, specifically applicable to the androgen-dependent mechanism of male pattern hair loss.
Multiple preclinical studies and a comprehensive 2022–2023 literature review have documented neuroprotective properties of Forsythia suspensa active components, particularly forsythoside A. Relevant conditions studied include Alzheimer's disease, Parkinson's disease, ischemic stroke, and peripheral neuropathy. All evidence is from animal/in vitro studies; human clinical trials are absent.
A 2019 Nutrients study demonstrated that a water extract of Forsythia suspensa significantly reduced ovariectomy-induced trabecular bone loss and inhibited RANKL-driven osteoclast formation in mice. A 2024 study showed forsythoside A mitigates diabetes-related osteoporosis via NRF2/GPX4. Evidence is preclinical; no human trials have been conducted.
Forsythia suspensa is traditionally and pharmacologically documented for the treatment of pneumonia, acting via anti-inflammatory and antiviral mechanisms. Forsythoside A has been shown to protect against LPS-induced acute lung injury and RSV-induced pneumonia in mouse models. Combination TCM formulas containing Forsythia have been used clinically in China for pneumonia, including COVID-19.
A 2022 preclinical study published in a peer-reviewed journal demonstrated that forsythoside A from Forsythia suspensa alleviated imiquimod-induced psoriasis-like dermatitis in mice by regulating Th17 cells and reducing IL-17A expression. The study identified dose-dependent reductions in skin redness, scaling, and keratinocyte proliferation. No human clinical trials have been conducted.
Forsythia is revered in TCM as the 'holy herb for ulcerative disorders' and has a long history of use for treating skin abscesses, boils, and internal abscesses of the lung and intestine. The Compendium of Materia Medica and classical texts document its use for carbuncles and suppurative sores. Modern phytochemical work confirms antibacterial activity of its active constituents, but no controlled human trials exist for abscess treatment specifically.
Forsythia is one of the 50 fundamental herbs in TCM and is traditionally used in formulas addressing acne and skin infections, exploiting its heat-clearing and detoxifying properties. It appears in classical formulas and modern TCM practice for acne. Preclinical data support antimicrobial and anti-inflammatory actions, but no dedicated human clinical trials for acne exist.
Forsythia is traditionally used in TCM for conditions of the lung meridian including bronchiolitis and upper respiratory infections. It is incorporated into combination preparations used intravenously or orally for bronchiolitis in clinical TCM settings. The evidence base for standalone bronchial use is primarily from traditional practice and preclinical studies.
Forsythia (Forsythia suspensa, Lian Qiao) is a key Traditional Chinese Medicine herb for acute respiratory infections including bronchitis and lung heat conditions. It is traditionally combined with honeysuckle in Yin Qiao San for respiratory infections. Its forsythosides and lignans have antiviral and anti-inflammatory activity. Evidence is primarily traditional and preclinical.
Forsythia suspensa (Lian Qiao) is a cornerstone herb in Traditional Chinese Medicine for febrile respiratory conditions equivalent to cold and flu, co-formulated with honeysuckle in the classical Yin Qiao San. Active forsythiaside A has demonstrated antiviral activity against influenza A in vitro. EBSCO includes Forsythia as part of proposed TCM treatments for cold and flu.
Reducing fever is one of Forsythia's primary traditional indications, documented in classical TCM texts including the Shen Nong Ben Cao. It forms part of classic antipyretic formulas such as Yin Qiao San and Shuanghuanglian, which have been used clinically in China for febrile illnesses. The formula Maxing Shigan decoction-Yinqiao powder (containing Forsythia) was shown in a clinical study to resolve fever in H1N1 influenza patients.
Forsythia is traditionally used in TCM for dispersing nodules and relieving lymphatic swelling, particularly scrofula (lymph node tuberculosis). Classical texts including the Compendium of Materia Medica document its use for swollen lymph nodes and tumor-like accumulations. Its TCM action of 'dispersing nodules' forms a core part of its historical use.
Forsythia is traditionally used in Chinese medicine formulas for breast abscesses and mastitis. Classical texts including 'The Jade Woodcutter's Medical Orders' describe specific formulas using Forsythia for breast abscess and nodules. Its antibacterial, anti-inflammatory actions provide mechanistic plausibility. No human clinical trials exist specifically for mastitis.
Nausea and vomiting are listed among the traditional indications for Forsythia in Chinese medicine, and it is described as having antiemetic properties in pharmacological reviews. Animal models using free radical-induced emesis have been used to screen its antiemetic compounds. Clinical human evidence is absent.
Forsythia is a primary ingredient in classic TCM formulas used for post-febrile and viral recovery states. Its 'heat-clearing and detoxifying' role addresses residual heat patterns that TCM associates with post-viral lingering illness. The formula LHQW containing Forsythia was recommended for COVID-19 treatment in Chinese national guidelines. Preclinical evidence for antiviral activity is strong; isolated human trial data are limited.
Forsythia is traditionally used in TCM for skin rashes, macules, and erysipelas (a severe bacterial skin rash). Classical texts including the Shennong's Herbal list it for erysipelas and macules. It is used in formulas for febrile skin eruptions and heat-pattern rashes. Preclinical data support its anti-inflammatory and anti-allergic properties.
Treating sore throat is one of Forsythia's most established traditional uses in TCM, documented in classical formulas including Yin Qiao San. It is commonly combined with honeysuckle for sore throat with febrile signs. Formula-based evidence from clinical use in China supports its application; Forsythia as a single agent for sore throat lacks dedicated human RCTs.
Tonsillitis is among the traditional indications for Forsythia in TCM, and it is used in classic formulas for acute tonsillitis and pharyngitis. Classical TCM sources combine it with burdock seed for tonsillitis specifically. Formula-based clinical applications in Chinese medicine include acute tonsillitis. No standalone human RCTs exist.
Forsythia suspensa fruit (Lian Qiao) is a principal TCM herb for upper respiratory infections with fever, sore throat, and inflammation. A key component of Shuanghuanglian (used in Chinese hospitals for URTI) and classical Yin Qiao San formula, its active forsythia glycosides show antiviral activity against influenza and RSV.
Forsythia suspensa (Lian Qiao) is a fundamental TCM anti-viral herb used for febrile and respiratory viral conditions for 2,000+ years. It contains forsythin, phillyrin, and rutin with antiviral activity against influenza and SARS-CoV-2. It is a component of classical TCM antiviral formulas including Shuang Huang Lian.
Forsythia has documented traditional use as a diuretic in TCM, with classical texts noting it 'smooths urination' and treats urinary stranguria. It is described in ethnopharmacological sources as having diuretic properties for fluid balance. No clinical or preclinical studies specifically evaluating this diuretic effect have been identified in the indexed literature.
Volver